These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 26176329

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic Amyloidosis.
    Sahota T, Berges A, Barton S, Cookson L, Zamuner S, Richards D.
    CPT Pharmacometrics Syst Pharmacol; 2015 Feb; 4(2):e15. PubMed ID: 26225229
    [Abstract] [Full Text] [Related]

  • 7. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.
    Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN.
    Nature; 2002 May 16; 417(6886):254-9. PubMed ID: 12015594
    [Abstract] [Full Text] [Related]

  • 8. Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component.
    Kolstoe SE, Ridha BH, Bellotti V, Wang N, Robinson CV, Crutch SJ, Keir G, Kukkastenvehmas R, Gallimore JR, Hutchinson WL, Hawkins PN, Wood SP, Rossor MN, Pepys MB.
    Proc Natl Acad Sci U S A; 2009 May 05; 106(18):7619-23. PubMed ID: 19372378
    [Abstract] [Full Text] [Related]

  • 9. An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 study.
    Richards D, Millns H, Cookson L, Lukas MA.
    Orphanet J Rare Dis; 2022 Jul 09; 17(1):259. PubMed ID: 35810311
    [Abstract] [Full Text] [Related]

  • 10. Out, Out--Making Amyloid's Candle Briefer.
    Comenzo RL.
    N Engl J Med; 2015 Sep 17; 373(12):1167-9. PubMed ID: 26376140
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Kinetic studies with iodine-123-labeled serum amyloid P component in patients with systemic AA and AL amyloidosis and assessment of clinical value.
    Jager PL, Hazenberg BP, Franssen EJ, Limburg PC, van Rijswijk MH, Piers DA.
    J Nucl Med; 1998 Apr 17; 39(4):699-706. PubMed ID: 9544684
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.
    Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB, Hawkins PN.
    Br J Haematol; 2003 Jul 17; 122(1):78-84. PubMed ID: 12823348
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.